2025
Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury
Baker M, Cantley L. Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury. Journal Of Clinical Investigation 2025, 135: e188358. PMID: 40091836, PMCID: PMC11910233, DOI: 10.1172/jci188358.Peer-Reviewed Original ResearchConceptsAcute kidney injuryTubular epithelial cellsKidney injuryTubular cellsCases of acute kidney injuryImmune-mediated processPersistence of inflammationBiphasic immune responseChronic kidney diseaseCell deathTubular cell injuryLymphocyte subsetsTubular repairCell cycle arrestOutflow obstructionTEC differentiationPreclinical findingsLymphocytic infiltrationProinflammatory macrophagesKidney diseaseModulate inflammationImmune responseActivated macrophagesMetabolic reprogrammingTubular castsEffects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderUse disorderPreclinical studiesClinical studiesReview of preclinical studiesConditioned place preferenceOpioid self-administrationEffects of psychedelicsPreclinical in vivo studiesOpioid use disorder treatmentFrequency of administrationPlace preferencePotential therapeutic effectsSelf-administrationWithdrawal symptomsPreclinical findingsMechanism of actionSafety profilePain studiesPsychedelicsMethodological quality assessmentClinical evidenceCardiovascular riskOpioidWeb of Science
2024
Neural mechanisms of psychedelic visual imagery
Stoliker D, Preller K, Novelli L, Anticevic A, Egan G, Vollenweider F, Razi A. Neural mechanisms of psychedelic visual imagery. Molecular Psychiatry 2024, 30: 1259-1266. PMID: 38862674, PMCID: PMC11919690, DOI: 10.1038/s41380-024-02632-3.Peer-Reviewed Original ResearchVisual association regionsVisual imageryConsistent with preclinical findingsInferior frontal gyrusSerotonergic psychedelic drugTop-down feedback connectionsFunctional MRI scansVisual areasDynamic causal modelingEffective connectivity modelsTop-down connectionsEarly visual areasFusiform gyrusFrontal gyrusClassic psychedelicsIntraparietal sulcusBehavioral measuresNeural mechanismsPsychedelic experiencePsychedelic drugsConnectivity changesAffect balancePlacebo-controlledPreclinical findingsCausal modelDe Novo Elastin Assembly Alleviates Development of Supravalvular Aortic Stenosis—Brief Report
Ellis M, Riaz M, Huang Y, Anderson C, Hoareau M, Li X, Luo H, Lee S, Park J, Luo J, Batty L, Huang Q, Lopez C, Reinhardt D, Tellides G, Qyang Y. De Novo Elastin Assembly Alleviates Development of Supravalvular Aortic Stenosis—Brief Report. Arteriosclerosis Thrombosis And Vascular Biology 2024, 44: 1674-1682. PMID: 38752350, PMCID: PMC11209776, DOI: 10.1161/atvbaha.124.320790.Peer-Reviewed Original ResearchSupravalvular aortic stenosisVascular smooth muscle cellsSmooth muscle cellsMuscle cellsAortic stenosisMedial vascular smooth muscle cellsVascular proliferative diseasesEpigallocatechin gallate treatmentProliferative abnormalitiesPreclinical findingsHeart failureLuminal occlusionMouse modelCell hyperproliferationDefective elastinProliferative diseasesCardiovascular disordersFormation of elastinTherapeutic interventionsElastin assemblyElastin depositionStenosisMiceAortic mechanicsImproper formationIntegrating and fragmenting memories under stress and alcohol
Loetscher K, Goldfarb E. Integrating and fragmenting memories under stress and alcohol. Neurobiology Of Stress 2024, 30: 100615. PMID: 38375503, PMCID: PMC10874731, DOI: 10.1016/j.ynstr.2024.100615.Peer-Reviewed Original ResearchMemory representationsMemory integrationMemory-guided behaviorPre-existing schemaEffects of alcoholMemory bindingAversive learningNegative affectCognitive mechanismsPreclinical findingsMemoryDesign appropriate interventionsIndividual experienceAppropriate interventionsFragmented memoryAlcoholCausal structureAffectBehaviorMultiple levelsFindingsRepresentationStressSchemaIntervention
2023
Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats
Asch R, Fowles K, Pietrzak R, Taylor J, Esterlis I. Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats. Chronic Stress 2023, 7: 24705470231215001. PMID: 38024327, PMCID: PMC10666551, DOI: 10.1177/24705470231215001.Peer-Reviewed Original ResearchPost-traumatic stress disorderReceptor availabilityFemale ratsPathophysiology of PTSDFootshock exposureMetabotropic glutamate receptor 5Recent preclinical findingsGlutamate receptor 5Positron emission tomographyPreclinical findingsClinical findingsFe ratsReceptor 5Lower baselineEmission tomographyGreater riskPET studiesRatsStress disorderDifferential involvementPassive copingSex differencesMalesPTSD susceptibilityBaseline
2022
Extra-Virgin Olive Oil Enhances the Blood–Brain Barrier Function in Mild Cognitive Impairment: A Randomized Controlled Trial
Kaddoumi A, Denney T, Deshpande G, Robinson J, Beyers R, Redden D, Praticò D, Kyriakides T, Lu B, Kirby A, Beck D, Merner N. Extra-Virgin Olive Oil Enhances the Blood–Brain Barrier Function in Mild Cognitive Impairment: A Randomized Controlled Trial. Nutrients 2022, 14: 5102. PMID: 36501136, PMCID: PMC9736478, DOI: 10.3390/nu14235102.Peer-Reviewed Original ResearchConceptsClinical Dementia RatingMild cognitive impairmentBBB permeabilityAlzheimer's diseaseProtective effectP-tau/t-tau ratioCognitive impairmentBlood-brain barrier breakdownBlood-brain barrier functionBrain connectivityBehavioral scoresAbnormal BBB permeabilityAD mouse modelClearance of AβT-tau ratioEarly Alzheimer's diseaseFunctional brain activationSecondary outcomesBrain atrophyControlled TrialsPrimary outcomePreclinical findingsBrain amyloidBlood biomarkersBarrier breakdownPositive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear
Lee B, Pothula S, Wu M, Kang H, Girgenti MJ, Picciotto MR, DiLeone RJ, Taylor JR, Duman RS. Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear. Molecular Psychiatry 2022, 27: 2580-2589. PMID: 35418600, PMCID: PMC9135632, DOI: 10.1038/s41380-022-01498-7.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderFear extinctionInfralimbic medial prefrontal cortexFear conditioning modelEnhanced fear extinctionFear-based behaviorsProlonged stress modelMedial prefrontal cortexSpontaneous recoveryIL-mPFCPTSD modelPTSD treatmentStress disorderPrefrontal cortexSPS modelN-methyl-D-aspartate receptor modulatorsBrain-derived neurotrophic factorN-methyl-D-aspartate receptorsBehavioral effectsIncreased attentionMPFCPreclinical findingsPyramidal neuronsNeurotrophic factorMale mice
2020
Acute neuroimmune stimulation impairs verbal memory in adults: A PET brain imaging study
Woodcock EA, Hillmer AT, Sandiego CM, Maruff P, Carson RE, Cosgrove KP, Pietrzak RH. Acute neuroimmune stimulation impairs verbal memory in adults: A PET brain imaging study. Brain Behavior And Immunity 2020, 91: 784-787. PMID: 33002632, PMCID: PMC7749814, DOI: 10.1016/j.bbi.2020.09.027.Peer-Reviewed Original ResearchConceptsMemory processesCognitive dysfunctionHippocampal memory processesBrain imaging studiesExecutive processesVerbal learningVerbal memoryExperimental paradigmCognitive deficitsPositron emission tomographyGreater decrementNeuroinflammatory dysfunctionNeurologic disordersPrevious findingsHealthy adultsDevelopment studiesMarker of microgliaImaging studiesNeuroimmune responseLPS administrationNeuroinflammatory signalingAdultsPreclinical findingsExperimental inductionDisorders
2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML
Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, Halene S, Xu T, Rothberg J, Lichenstein H. LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML. Blood Advances 2019, 3: 3661-3673. PMID: 31751472, PMCID: PMC6880894, DOI: 10.1182/bloodadvances.2019001068.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorDisease Models, AnimalDose-Response Relationship, DrugDrug Resistance, NeoplasmDrug SynergismEpigenesis, Geneticfms-Like Tyrosine Kinase 3Gene DuplicationGene Expression Regulation, LeukemicHumansLeukemia, Myeloid, AcuteMiceMutationProtein Kinase InhibitorsConceptsAcute myeloid leukemiaAML cell linesFLT3 inhibitorsFLT3-ITDSingle agentPositive acute myeloid leukemiaFLT3 inhibitor therapyStromal-conditioned mediumInitial clinical responseInternal tandem duplication mutationsFLT3-ITD patientsPoor patient prognosisXenograft mouse modelCell linesFLT3 kinase inhibitorsTandem duplication mutationsDiscovery of synergyWide CRISPR screenClinical responseTyrosine kinase receptorsInhibitor therapyPreclinical findingsBcl-2 inhibitorsMechanisms of resistancePatient prognosis
2017
MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis
Sahu A, Jha P, Prabhakar A, Singh H, Gupta N, Chatterjee T, Tyagi T, Sharma S, Kumari B, Singh S, Nair V, Goel S, Ashraf M. MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis. EBioMedicine 2017, 26: 175-186. PMID: 29217135, PMCID: PMC5832640, DOI: 10.1016/j.ebiom.2017.11.022.Peer-Reviewed Original ResearchConceptsMiR-145 levelsTissue factorVenous thromboembolismMiR-145Thrombus formationTF levelsTargeting tissue factorPromising therapeutic strategyCardiovascular complicationsThrombus loadVenous thrombosisCoagulation variablesPreclinical findingsTherapeutic strategiesVT patientsTF expressionInverse correlationKey moleculesPatientsVivo experimentsUndescribed roleTarget genesVTThromboembolismLevelsEvaluating oral flavorant effects on nicotine self-administration behavior and phasic dopamine signaling
Wickham RJ, Nunes EJ, Hughley S, Silva P, Walton SN, Park J, Addy NA. Evaluating oral flavorant effects on nicotine self-administration behavior and phasic dopamine signaling. Neuropharmacology 2017, 128: 33-42. PMID: 28943284, PMCID: PMC5714675, DOI: 10.1016/j.neuropharm.2017.09.029.Peer-Reviewed Original ResearchConceptsSelf-administration behaviorNucleus accumbensNicotine self-administration behaviorIntravenous self-administration paradigmFast-scan cyclic voltammetryPublic health policy decisionsPhasic DA signalingTobacco product useProgressive ratio taskSelf-administration paradigmTwo-bottle choice testPhasic DA releaseHealth policy decisionsTobacco product regulationOral mentholOral nicotineOral sucroseNicotine administrationPreclinical findingsDA releaseMale ratsOral administrationSmoking behaviorNicotine aversionMenthol effectsEffect of doxazosin on stress reactivity and the ability to resist smoking
Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, Tetrault JM, Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. Journal Of Psychopharmacology 2017, 31: 830-840. PMID: 28440105, PMCID: PMC5823502, DOI: 10.1177/0269881117699603.Peer-Reviewed Original ResearchConceptsTobacco cravingCortisol levelsSubsequent ad libitum smokingEffects of doxazosinAd libitum smokingNumber of cigarettesNicotine-motivated behaviorsSmoking lapse behaviorΑ1-adrenergic antagonistNicotine-deprived smokersTitration periodPreclinical findingsSmoking cessationNoradrenergic systemTreatment strategiesDoxazosinSmoking behaviorSmokingHuman laboratoryPhysiologic reactivityPilot studyStress reactivityEffects of stressCigarettesStress imageryActivation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia
Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 4763-4768. PMID: 28420787, PMCID: PMC5422823, DOI: 10.1073/pnas.1620458114.Peer-Reviewed Original ResearchConceptsExpression of NLRP3Venous thrombosisVenous thromboembolismIL-1βCaspase-1Activation of NLRP3Acute thrombotic eventsHypoxic conditionsIL-1β secretionNLRP3 inflammasome complexHypoxia-inducible factorThromboembolic eventsProinflammatory stateSystemic hypoxiaThrombotic eventsPreclinical findingsAltered hemostasisRisk factorsCardiovascular conditionsCommon causeInflammasome activationThrombosisHealthy individualsPyrin domainHIF-1α
2016
Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects
Zanda M, Fadda P, Chiamulera C, Fratta W, Fattore L. Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects. Behavioural Pharmacology 2016, 27: 489-496. PMID: 27128862, DOI: 10.1097/fbp.0000000000000241.Peer-Reviewed Original ResearchConceptsEffects of methoxetamineN-methyl-d-aspartate receptor antagonistic propertiesPsychoactive substancesReceptor antagonist propertiesOccurrence of adverse effectsAdverse pharmacological effectsDopamine neurotransmissionMesolimbic pathwayAntidepressant activityPreclinical dataPreclinical findingsAntagonistic propertiesLong-term effectsPharmacological effectsStimulatory effectMethoxetamineAdverse effectsKetamineLegal highsResearch chemicalsToxicological effectsPhencyclidineDopamineNeurotransmissionIncreasing numberIrreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go
Savic LJ, Chapiro J, Hamm B, Gebauer B, Collettini F. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. RöFo 2016, 188: 735-745. PMID: 27074423, DOI: 10.1055/s-0042-104203.Peer-Reviewed Original ResearchConceptsClinical evidenceIrreversible electroporationInterventional oncologyPancreatic irreversible electroporationSite-specific complicationsAvailable clinical evidenceUse of IRELimited clinical evidenceFavorable safety profileTolerable morbidityOncologic efficacyPreclinical findingsBile ductSafety profileNeurovascular bundleInvasive treatmentLung parenchymaAblation therapySolid tumorsClinical settingTumor ablation therapyHeat sink effectNon-thermal fashionLiverTumor ablation
2011
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma
Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opinion On Drug Metabolism & Toxicology 2011, 7: 1141-1152. PMID: 21726160, DOI: 10.1517/17425255.2011.595404.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaRefractory peripheral T-cell lymphomaPhase I/II trialEarly phase I/II trialsCutaneous T-cell lymphomaAggressive T-cell lymphomaT-cell lymphoma subtypesFrequent adverse eventsStem cell transplantationT-cell neoplasmsII trialAdverse eventsMost patientsHodgkin's diseasePreclinical findingsClinical efficacyLymphoma trialsPoor outcomeConventional therapyHodgkin's lymphomaReversible thrombocytopeniaHematologic malignanciesClinical trialsClinical studies
2007
Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes
Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. Journal Of Clinical Oncology 2007, 25: 586-586. DOI: 10.1200/jco.2007.25.18_suppl.586.Peer-Reviewed Original ResearchClinical responseTaxane sensitivityPreoperative therapyPrognostic factorsHER2 tumorsProspective studyBreast cancerDocetaxel/capecitabineDocetaxel/doxorubicinTaxane-containing regimensLarge prospective studiesPrimary breast cancerClinical prognostic factorsHER2- breast cancerNovel predictive markerCyclin-dependent kinase 1Breast tumor responseLogistic regression modelsEvaluable ptsAdjuvant therapyClinical outcomesPreclinical findingsPredictive markerTumor responseHER2 overexpression
2003
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.Peer-Reviewed Original ResearchConceptsATF2 expressionTranscription factor 2Melanoma specimensUseful prognostic markerEarly-stage melanomaWeak cytoplasmic stainingStrong nuclear stainingFactor 2Mean followCutaneous specimensLocalized diseaseOverall survivalIndependent predictorsPreclinical findingsClark levelClinicopathological dataPatient survivalPoor outcomePrognostic valueWorse outcomesPrognostic markerPoor survivalPreclinical modelsClinical significanceImmunohistochemical staining
1997
Effects of Antiglucocorticoid Treatment on 5-HT1A Function in Depressed Patients and Healthy Subjects
Price L, Cappiello A, Malison R, McDougle C, Pelton G, Schöllnhammer G, Heninger G. Effects of Antiglucocorticoid Treatment on 5-HT1A Function in Depressed Patients and Healthy Subjects. Neuropsychopharmacology 1997, 17: 246-257. PMID: 9326749, DOI: 10.1016/s0893-133x(97)00049-3.Peer-Reviewed Original ResearchConceptsDepressed patientsReceptor functionHealthy control subjectsUnipolar depressed patientsAntiglucocorticoid treatmentAntidepressant actionGlucocorticoid modulationPreclinical findingsAdrenal axisControl subjectsAntidepressant activityClinical studiesTest doseHealthy subjectsReceptor sensitivityIpsapironeCortisol biosynthesisKetoconazoleDepressionPatientsBehavioral responsesSubjectsGlucocorticoidsAgonistsNeuroendocrine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply